

Srdan Verstovsek,, of Medicine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5704075/publications.pdf>

Version: 2024-02-01

320
papers

21,032
citations

13865

67
h-index

11939

134
g-index

325
all docs

325
docs citations

325
times ranked

10789
citing authors

#	ARTICLE	IF	CITATIONS
1	A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. <i>New England Journal of Medicine</i> , 2012, 366, 799-807.	27.0	1,738
2	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. <i>Leukemia</i> , 2022, 36, 1703-1719.	7.2	1,211
3	Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. <i>New England Journal of Medicine</i> , 2010, 363, 1117-1127.	27.0	1,046
4	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2011, 29, 761-770.	1.6	724
5	Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. <i>New England Journal of Medicine</i> , 2015, 372, 426-435.	27.0	720
6	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i> , 2018, 32, 1057-1069.	7.2	415
7	Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. <i>Blood</i> , 2006, 107, 3469-3473.	1.4	371
8	Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera. <i>Journal of Clinical Oncology</i> , 2009, 27, 5418-5424.	1.6	367
9	Effective Treatment of Acute Promyelocytic Leukemia With All- <i>Trans</i> -Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. <i>Journal of Clinical Oncology</i> , 2009, 27, 504-510.	1.6	355
10	Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. <i>Nature</i> , 2012, 489, 155-159.	27.8	320
11	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). <i>Blood</i> , 2006, 108, 1497-1503.	1.4	317
12	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. <i>Journal of Hematology and Oncology</i> , 2017, 10, 55.	17.0	302
13	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. <i>Blood</i> , 2013, 122, 1395-1398.	1.4	286
14	Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 127-140.	46.4	261
15	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis. <i>JAMA Oncology</i> , 2018, 4, 652.	7.1	261
16	Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 1933-1940.	7.0	246
17	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. <i>Haematologica</i> , 2015, 100, 479-488.	3.5	246
18	Lenalidomide therapy in myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2006, 108, 1158-1164.	1.4	239

#	ARTICLE	IF	CITATIONS
19	Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5401-10.	7.1	238
20	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood, 2017, 129, 1275-1283.	1.4	214
21	Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis. Journal of Clinical Oncology, 2009, 27, 4563-4569.	1.6	213
22	Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematology, the, 2018, 5, e73-e81.	4.6	211
23	Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. Journal of Hematology and Oncology, 2017, 10, 156.	17.0	210
24	Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood, 2012, 120, 1202-1209.	1.4	205
25	The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leukemia Research, 2009, 33, 1199-1203.	0.8	203
26	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica, 2015, 100, 1139-1145.	3.5	203
27	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematology, the, 2020, 7, e724-e736.	4.6	201
28	Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood, 2014, 123, 2645-2651.	1.4	192
29	Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood, 2017, 130, 1125-1131.	1.4	180
30	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer, 2014, 120, 513-520.	4.1	165
31	Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood, 2015, 126, 790-797.	1.4	162
32	The natural history and treatment outcome of blast phase BCR-ABL ⁺ myeloproliferative neoplasms. Blood, 2008, 112, 1628-1637.	1.4	152
33	Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis. Journal of Clinical Oncology, 2009, 27, 4760-4766.	1.6	152
34	Phase II Study of Dasatinib in Philadelphia Chromosome ⁻ Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis. Clinical Cancer Research, 2008, 14, 3906-3915.	7.0	151
35	The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood, 2015, 126, 1551-1554.	1.4	151
36	Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leukemia Research, 2009, 33, 1481-1484.	0.8	146

#	ARTICLE	IF	CITATIONS
37	Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. <i>Haematologica</i> , 2013, 98, 1865-1871.	3.5	143
38	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. <i>Haematologica</i> , 2016, 101, 821-829.	3.5	140
39	Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. <i>Journal of Experimental Medicine</i> , 2016, 213, 1723-1740.	8.5	128
40	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 432-440.	2.0	127
41	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013, 121, 2393-2401.	1.4	122
42	Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. <i>Haematologica</i> , 2016, 101, 660-671.	3.5	120
43	Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2009, 27, 5587-5593.	1.6	117
44	Staging of chronic myeloid leukemia in the imatinib era. <i>Cancer</i> , 2006, 106, 1306-1315.	4.1	107
45	PEG-IFN-2b therapy in BCR-ABL-negative myeloproliferative disorders. <i>Cancer</i> , 2007, 110, 2012-2018.	4.1	107
46	Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e165-e175.	4.6	96
47	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. <i>American Journal of Hematology</i> , 2020, 95, 594-603.	4.1	96
48	Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. <i>Lancet</i> , 2017, 389, 612-620.	13.7	95
49	Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 577-588.	4.1	94
50	Therapeutic potential of JAK2 inhibitors. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 636-642.	2.5	93
51	Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. <i>Lancet Haematology</i> , 2020, 7, e226-e237.	4.6	93
52	Thalidomide therapy for myelofibrosis with myeloid metaplasia. <i>Cancer</i> , 2006, 106, 1974-1984.	4.1	90
53	Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells. <i>Clinical Cancer Research</i> , 2011, 17, 7347-7358.	7.0	90
54	Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. <i>Journal of Hematology and Oncology</i> , 2013, 6, 81.	17.0	89

#	ARTICLE	IF	CITATIONS
55	Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. <i>Haematologica</i> , 2017, 102, 327-335.	3.5	87
56	JAK2 inhibitors for myeloproliferative neoplasms: what is next?. <i>Blood</i> , 2017, 130, 115-125.	1.4	86
57	The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. <i>British Journal of Haematology</i> , 2013, 161, 508-516.	2.5	83
58	Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. <i>Journal of Experimental Pharmacology</i> , 2016, Volume 8, 11-19.	3.2	83
59	A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. <i>Haematologica</i> , 2017, 102, 94-102.	3.5	80
60	Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. <i>Nature Medicine</i> , 2021, 27, 2183-2191.	30.7	78
61	BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. <i>Leukemia</i> , 2017, 31, 678-687.	7.2	77
62	ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. <i>Blood Advances</i> , 2020, 4, 4282-4291.	5.2	77
63	Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: Clinical significance and comparison of chromosomal abnormalities in <i>SM</i> and <i>AHNMD</i> components. <i>American Journal of Hematology</i> , 2013, 88, 219-224.	4.1	76
64	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76
65	EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. <i>Blood</i> , 2007, 109, 315-322.	1.4	69
66	Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. <i>Leukemia Research</i> , 2015, 39, 950-956.	0.8	69
67	The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). <i>British Journal of Haematology</i> , 2017, 176, 76-85.	2.5	69
68	Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. <i>Annals of Hematology</i> , 2017, 96, 1113-1120.	1.8	68
69	Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia. <i>Clinical Cancer Research</i> , 2009, 15, 368-373.	7.0	67
70	Mechanisms of thrombogenesis in polycythemia vera. <i>Blood Reviews</i> , 2015, 29, 215-221.	5.7	67
71	A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 171-176.	0.4	67
72	JAK2 inhibitors: What's the true therapeutic potential?. <i>Blood Reviews</i> , 2011, 25, 53-63.	5.7	65

#	ARTICLE	IF	CITATIONS
73	Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. <i>Leukemia Research</i> , 2012, 36, 1124-1127.	0.8	65
74	Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. <i>Journal of Hematology and Oncology</i> , 2016, 9, 137.	17.0	65
75	Novel approaches in the treatment of systemic mastocytosis. <i>Cancer</i> , 2006, 107, 1429-1439.	4.1	63
76	Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. <i>Journal of Hematology and Oncology</i> , 2018, 11, 42.	17.0	63
77	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	5.2	63
78	A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. <i>Blood</i> , 2018, 132, 1664-1674.	1.4	62
79	Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1572-1611.	4.9	61
80	Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. <i>Haematologica</i> , 2016, 101, 1133-1143.	3.5	60
81	Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. <i>Journal of Clinical Oncology</i> , 2022, 40, 1671-1680.	1.6	60
82	Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. <i>Leukemia</i> , 2020, 34, 799-810.	7.2	58
83	The JAK kinase inhibitor CPâ€690,550 supresses the growth of human polycythemia vera cells carrying the JAK2^{V617F} mutation. <i>Cancer Science</i> , 2008, 99, 1265-1273.	3.9	57
84	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1876-1883.	5.2	56
85	Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. <i>Blood</i> , 2011, 118, 899-902.	1.4	55
86	A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2018, 93, 277-285.	4.1	54
87	A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia. <i>Blood</i> , 2019, 134, 557-557.	1.4	54
88	Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. <i>International Journal of General Medicine</i> , 2014, 7, 89.	1.8	53
89	Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. <i>Leukemia Research</i> , 2017, 59, 110-116.	0.8	53
90	Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. <i>Blood</i> , 2017, 130, 1768-1771.	1.4	52

#	ARTICLE	IF	CITATIONS
91	Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2015, 56, 2092-2097.	1.3	51
92	Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement. <i>Cancer</i> , 2011, 117, 4869-4877.	4.1	50
93	The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. <i>Haematologica</i> , 2016, 101, e482-e484.	3.5	50
94	Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. <i>Leukemia and Lymphoma</i> , 2014, 55, 121-127.	1.3	49
95	JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives. <i>HemaSphere</i> , 2020, 4, e424.	2.7	49
96	Advanced systemic mastocytosis: the impact of <scp>KIT</scp> mutations in diagnosis, treatment, and progression. <i>European Journal of Haematology</i> , 2013, 90, 89-98.	2.2	48
97	Management of patients with systemic mastocytosis: Review of M. D. Anderson Cancer Center experience. <i>American Journal of Hematology</i> , 2004, 77, 209-214.	4.1	47
98	Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?. <i>Hematological Oncology</i> , 2006, 24, 181-188.	1.7	47
99	Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 555-559.	2.0	46
100	Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. <i>OncoTargets and Therapy</i> , 2013, 7, 13.	2.0	46
101	Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. <i>Haematologica</i> , 2015, 100, 1058-63.	3.5	46
102	Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. <i>European Journal of Haematology</i> , 2016, 97, 192-200.	2.2	46
103	Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis. <i>Postgraduate Medicine</i> , 2013, 125, 128-135.	2.0	45
104	Investigational Janus kinase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 687-699.	4.1	44
105	PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study. <i>Blood</i> , 2018, 132, 686-686.	1.4	44
106	Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 81-86.	2.3	43
107	Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. <i>Blood</i> , 2019, 133, 2348-2351.	1.4	43
108	Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. <i>Leukemia Research</i> , 2014, 38, 316-322.	0.8	42

#	ARTICLE	IF	CITATIONS
109	MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. <i>Blood</i> , 2019, 134, 670-670.	1.4	42
110	JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. <i>Blood</i> , 2015, 125, 3352-3353.	1.4	41
111	A phase 2 study of simtuzumab in patients with primary, post-essential thrombocythemia myelofibrosis. <i>British Journal of Haematology</i> , 2017, 176, 939-949.	2.5	40
112	Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. <i>European Journal of Haematology</i> , 2018, 100, 257-263.	2.2	40
113	Mutational landscape of myelodysplastic/myeloproliferative neoplasm "unclassifiable". <i>Blood</i> , 2018, 132, 2100-2103.	1.4	40
114	Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis. <i>Clinical Cancer Research</i> , 2010, 16, 1988-1996.	7.0	39
115	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. <i>Haematologica</i> , 2014, 99, 292-298.	3.5	38
116	A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. <i>Leukemia Research</i> , 2017, 61, 89-95.	0.8	38
117	The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. <i>Annals of Hematology</i> , 2017, 96, 1595-1604.	1.8	38
118	The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 415-421.	0.4	38
119	Outcome of patients with IDH1/2-mutated "myeloproliferative neoplasm AML in the era of IDH inhibitors. <i>Blood Advances</i> , 2020, 4, 5336-5342.	5.2	37
120	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2489-2492.	7.2	37
121	Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1125-1142.	2.3	36
122	Momelotinib: an emerging treatment for myelofibrosis patients with anemia. <i>Journal of Hematology and Oncology</i> , 2022, 15, 7.	17.0	36
123	A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. <i>Leukemia Research</i> , 2017, 60, 11-17.	0.8	35
124	Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. <i>Blood Advances</i> , 2021, 5, 2156-2164.	5.2	33
125	Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR- β -expressing cells. <i>Leukemia Research</i> , 2006, 30, 1499-1505.	0.8	32
126	The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2018, 97, 2071-2080.	1.8	32

#	ARTICLE	IF	CITATIONS
127	Targeting nuclear β -catenin as therapy for post-myeloproliferative neoplasm secondary AML. <i>Leukemia</i> , 2019, 33, 1373-1386.	7.2	32
128	Givinostat: an emerging treatment for polycythemia vera. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 525-536.	4.1	32
129	Advances in the Therapy of Chronic Idiopathic Myelofibrosis. <i>Oncologist</i> , 2006, 11, 929-943.	3.7	31
130	Practical management of patients with myelofibrosis receiving ruxolitinib. <i>Expert Review of Hematology</i> , 2013, 6, 511-523.	2.2	31
131	Comorbidities predict worse prognosis in patients with primary myelofibrosis. <i>Cancer</i> , 2014, 120, 2996-3002.	4.1	31
132	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. <i>Future Oncology</i> , 2021, 17, 1449-1458.	2.4	31
133	Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. <i>Blood</i> , 2014, 124, 713-713.	1.4	31
134	A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. <i>Cancer</i> , 2007, 110, 955-964.	4.1	30
135	The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review. <i>Leukemia Research</i> , 2017, 58, 14-22.	0.8	30
136	An accurate, simple prognostic model consisting of age, <i>JAK2</i> , <i>CALR</i> , and <i>MPL</i> mutation status for patients with primary myelofibrosis. <i>Haematologica</i> , 2017, 102, 79-84.	3.5	30
137	Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. <i>Leukemia Research</i> , 2014, 38, 1126-1129.	0.8	29
138	<i>SMAC</i> mimetics as potential cancer therapeutics in myeloid malignancies. <i>British Journal of Haematology</i> , 2019, 185, 219-231.	2.5	29
139	Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts $\leq 100,000/\mu\text{l}$. <i>Blood</i> , 2016, 128, LBA-5-LBA-5.	1.4	29
140	Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 663-670.	2.4	28
141	Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera – single center experience. <i>Leukemia and Lymphoma</i> , 2016, 57, 237-239.	1.3	28
142	PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks. <i>Blood</i> , 2015, 126, 56-56.	1.4	28
143	Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2018, 97, 109-121.	1.8	27
144	Mechanistic basis and efficacy of targeting the β -catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors. <i>Blood</i> , 2020, 135, 1255-1269.	1.4	27

#	ARTICLE	IF	CITATIONS
145	Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. <i>Haematologica</i> , 2022, 107, 1599-1607.	3.5	27
146	Accelerated Phase of Myeloproliferative Neoplasms. <i>Acta Haematologica</i> , 2021, 144, 484-499.	1.4	26
147	Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis. <i>Cancer</i> , 2011, 117, 5439-5449.	4.1	25
148	Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1393-1403.	4.1	25
149	Updates in the management of polycythemia vera and essential thrombocythemia. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071987005.	2.5	25
150	Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study. <i>Blood</i> , 2019, 134, 4163-4163.	1.4	25
151	Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. <i>Leukemia and Lymphoma</i> , 2014, 55, 2685-2690.	1.3	24
152	Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. <i>Blood Cancer Journal</i> , 2021, 11, 98.	6.2	24
153	Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study. <i>Blood</i> , 2020, 136, 47-48.	1.4	24
154	Eosinophilia in Hematologic Disorders. <i>Immunology and Allergy Clinics of North America</i> , 2015, 35, 439-452.	1.9	23
155	Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?. <i>British Journal of Haematology</i> , 2017, 176, 352-364.	2.5	23
156	Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. <i>Investigational New Drugs</i> , 2011, 29, 818-826.	2.6	22
157	Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. <i>Leukemia Research</i> , 2017, 56, 52-59.	0.8	22
158	Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. <i>Blood</i> , 2016, 128, 478-478.	1.4	22
159	Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. <i>Leukemia and Lymphoma</i> , 2022, 63, 694-702.	1.3	22
160	Interferon α therapy for patients with essential thrombocythemia. <i>Cancer</i> , 2005, 103, 2551-2557.	4.1	21
161	Significance of cytogenetic abnormalities in patients with polycythemia vera. <i>Leukemia and Lymphoma</i> , 2013, 54, 2667-2670.	1.3	21
162	Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. <i>Leukemia Research</i> , 2015, 39, 822-827.	0.8	21

#	ARTICLE	IF	CITATIONS
163	Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 479-487.	0.4	21
164	Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome. <i>Leukemia Research</i> , 2017, 59, 105-109.	0.8	21
165	The Rationale for Immunotherapy in Myeloproliferative Neoplasms. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 310-327.	2.3	21
166	Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 1855-1866.	4.1	21
167	The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis. <i>Blood</i> , 2020, 136, 49-50.	1.4	21
168	In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 427-432.	2.3	20
169	New approaches in the treatment of myelofibrosis. <i>Cancer</i> , 2005, 103, 32-43.	4.1	20
170	Pegylated Interferon Therapy for Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 409-416.	2.7	20
171	New JAK2 inhibitors for myeloproliferative neoplasms. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 961-972.	4.1	20
172	Management of Myelofibrosis-Related Cytopenias. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 164-172.	2.3	20
173	A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1767-1774.	1.3	20
174	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. <i>HemaSphere</i> , 2021, 5, e562.	2.7	20
175	Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. <i>Annals of Hematology</i> , 2022, 101, 131-137.	1.8	20
176	Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. <i>Cancer</i> , 2020, 126, 4322-4331.	4.1	19
177	Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis. <i>Blood</i> , 2019, 134, 558-558.	1.4	19
178	Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. <i>Leukemia and Lymphoma</i> , 2010, 51, 269-274.	1.3	18
179	Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2013, 54, 2537-2539.	1.3	18
180	Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. <i>Leukemia and Lymphoma</i> , 2016, 57, 1054-1059.	1.3	18

#	ARTICLE	IF	CITATIONS
181	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. <i>British Journal of Haematology</i> , 2022, 198, 317-327.	2.5	18
182	Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. <i>Lancet Haematology</i> , 2022, 9, e434-e444.	4.6	18
183	The evolution and clinical relevance of prognostic classification systems in myelofibrosis. <i>Cancer</i> , 2016, 122, 681-692.	4.1	17
184	Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. <i>Leukemia Research</i> , 2016, 48, 1-5.	0.8	17
185	A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. <i>Blood Advances</i> , 2019, 3, 2264-2271.	5.2	17
186	Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1439-1445.	2.0	17
187	Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. <i>Blood Advances</i> , 2021, 5, 3163-3173.	5.2	17
188	Avapritinib for Systemic Mastocytosis. <i>Expert Review of Hematology</i> , 2021, 14, 687-696.	2.2	17
189	Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/JAK2 Inhibitor, for Patients with Intermediate to High Risk Myelofibrosis. <i>Blood</i> , 2019, 134, 555-555.	1.4	17
190	Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. <i>Cancer Science</i> , 2007, 98, 1223-1225.	3.9	16
191	Therapy with JAK2 Inhibitors for Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 1083-1099.	2.2	16
192	Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib. <i>Blood</i> , 2019, 134, 668-668.	1.4	16
193	Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts $\leq 100,000/\mu\text{l}$. <i>Blood</i> , 2013, 122, 395-395.	1.4	16
194	Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF). <i>Blood</i> , 2016, 128, 1936-1936.	1.4	16
195	Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial. <i>Blood</i> , 2021, 138, 141-141.	1.4	16
196	Improved survival of patients with myelofibrosis in the last decade: Single-center experience. <i>Cancer</i> , 2022, . .	4.1	16
197	Kit Mutations. <i>Immunology and Allergy Clinics of North America</i> , 2018, 38, 411-428.	1.9	15
198	Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. <i>Annals of Hematology</i> , 2019, 98, 1611-1616.	1.8	15

#	ARTICLE	IF	CITATIONS
199	Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count $\leq 50,000/\text{mL}$). <i>Blood</i> , 2019, 134, 4175-4175.	1.4	15
200	Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia. <i>Leukemia Research</i> , 2022, 115, 106809.	0.8	15
201	Primary autoimmune myelofibrosis: a case report and review of the literature. <i>International Journal of Hematology</i> , 2017, 105, 536-539.	1.6	14
202	Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 460-468.	2.3	14
203	LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial. <i>Blood</i> , 2018, 132, 687-687.	1.4	14
204	Long-Term Results from a Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea. <i>Blood</i> , 2014, 124, 1847-1847.	1.4	14
205	Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7001-7001.	1.6	14
206	Myelofibrosis osteoclasts are clonal and functionally impaired. <i>Blood</i> , 2019, 133, 2320-2324.	1.4	13
207	Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms. <i>Cancers</i> , 2020, 12, 2891.	3.7	13
208	Management of myelofibrosis after ruxolitinib failure. <i>Leukemia and Lymphoma</i> , 2020, 61, 1797-1809.	1.3	13
209	A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3K $\hat{\nu}$ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis. <i>Blood</i> , 2018, 132, 353-353.	1.4	13
210	Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. <i>International Journal of Hematology</i> , 2009, 90, 58-63.	1.6	12
211	Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation. <i>International Journal of Hematology</i> , 2009, 90, 522-525.	1.6	12
212	MER1, a novel organic arsenic derivative, has potent PML-RAR $\hat{\nu}$ - independent cytotoxic activity against leukemia cells. <i>Investigational New Drugs</i> , 2010, 28, 402-412.	2.6	12
213	Immunotherapy based approaches in myelofibrosis. <i>Expert Review of Hematology</i> , 2017, 10, 903-914.	2.2	12
214	Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. <i>Annals of Hematology</i> , 2018, 97, 1183-1191.	1.8	12
215	New Concepts of Treatment for Patients with Myelofibrosis. <i>Current Treatment Options in Oncology</i> , 2019, 20, 5.	3.0	12
216	Paradigm shift: combination BET and JAK inhibition in myelofibrosis. <i>Leukemia</i> , 2021, 35, 3361-3363.	7.2	12

#	ARTICLE	IF	CITATIONS
217	Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients. <i>Blood</i> , 2020, 136, 51-52.	1.4	12
218	Disease Modification in Myelofibrosis: An Elusive Goal?. <i>Journal of Clinical Oncology</i> , 2022, 40, 1147-1154.	1.6	12
219	Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. <i>International Review of Cell and Molecular Biology</i> , 2022, 366, 83-124.	3.2	12
220	Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib. <i>BMC Nephrology</i> , 2015, 16, 121.	1.8	11
221	New Therapeutic Approaches in Polycythemia Vera. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S27-S33.	0.4	11
222	Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 909-917.	1.3	11
223	Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 318-327.e6.	0.4	11
224	SOHO State of the Art Updates and Next Questions: Identifying and Treating “Progression” in Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 641-649.	0.4	11
225	Phase II study of single-agent nivolumab in patients with myelofibrosis. <i>Annals of Hematology</i> , 2021, 100, 2957-2960.	1.8	11
226	Efficacy of ruxolitinib for myelofibrosis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1465-1473.	1.8	10
227	Ruxolitinib for the treatment of patients with polycythemia vera. <i>Expert Review of Hematology</i> , 2015, 8, 391-401.	2.2	10
228	Ruxolitinib dose management as a key to long-term treatment success. <i>International Journal of Hematology</i> , 2016, 104, 420-429.	1.6	10
229	Investigational Janus kinase inhibitors in development for myelofibrosis. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 723-734.	4.1	10
230	A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis. <i>Blood</i> , 2020, 136, 39-40.	1.4	10
231	Arsenic derivatives as therapeutic agents for hematologic malignancies. <i>Leukemia Research</i> , 2004, 28, 901-903.	0.8	9
232	Treatment of systemic mastocytosis with denileukin diftitox. <i>American Journal of Hematology</i> , 2007, 82, 1124-1124.	4.1	9
233	Chromosome 5q deletion is extremely rare in patients with myelofibrosis. <i>Leukemia Research</i> , 2013, 37, 552-555.	0.8	9
234	Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities. <i>Leukemia Research</i> , 2015, 39, 419-423.	0.8	9

#	ARTICLE	IF	CITATIONS
235	Myelofibrosis: an update on drug therapy in 2016. Expert Opinion on Pharmacotherapy, 2016, 17, 2375-2389.	1.8	9
236	Mutational profiling in myelofibrosis: implications for management. International Journal of Hematology, 2020, 111, 192-199.	1.6	9
237	Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden. Blood Advances, 2020, 4, 5929-5935.	5.2	9
238	Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed/refractory chronic myelomonocytic leukemia (CMML).. Journal of Clinical Oncology, 2019, 37, 7059-7059.	1.6	9
239	SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 210-223.	0.4	9
240	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Modern Pathology, 2021, , .	5.5	9
241	Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update. Cancers, 2022, 14, 3474.	3.7	9
242	Preclinical and clinical experience with dasatinib in philadelphia chromosome-negative leukemias and myeloid disorders. Leukemia Research, 2009, 33, 617-623.	0.8	8
243	Treatment of aggressive systemic mastocytosis with daclizumab. Leukemia and Lymphoma, 2010, 51, 540-542.	1.3	8
244	Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes. PLoS ONE, 2019, 14, e0222912.	2.5	8
245	Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States. Annals of Hematology, 2020, 99, 2555-2564.	1.8	8
246	Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. British Journal of Haematology, 2021, 193, 1004-1008.	2.5	8
247	Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data. Blood, 2021, 138, 2568-2568.	1.4	8
248	Pregnancy in a patient with hypereosinophilic syndrome. Leukemia Research, 2009, 33, 186-187.	0.8	7
249	Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis. Leukemia and Lymphoma, 2013, 54, 1959-1964.	1.3	7
250	Clinical significance of microcytosis in patients with primary myelofibrosis. Leukemia Research, 2014, 38, 1212-1216.	0.8	7
251	Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. Annals of Hematology, 2017, 96, 733-738.	1.8	7
252	SOHO State-of-the-Art Update and Next Questions: MPN. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 1-12.	0.4	7

#	ARTICLE	IF	CITATIONS
253	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 2811-2820.	1.3	7
254	BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53WT relapsed/refractory (R/R) myelofibrosis (MF).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS7057-TPS7057.	1.6	7
255	Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients. <i>Blood</i> , 2018, 132, 4282-4282.	1.4	7
256	GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes. <i>Cell Death and Disease</i> , 2022, 13, .	6.3	7
257	Breakthroughs in myeloproliferative neoplasms. <i>Hematology</i> , 2012, 17, s55-s58.	1.5	6
258	Novel and emerging therapies for the treatment of polycythemia vera. <i>Expert Review of Hematology</i> , 2015, 8, 101-113.	2.2	6
259	Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis. <i>Blood</i> , 2016, 128, 877-880.	1.4	6
260	Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis. <i>Hematological Oncology</i> , 2018, 36, 701-708.	1.7	6
261	Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis. <i>British Journal of Haematology</i> , 2019, 185, 382-386.	2.5	6
262	Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare $JAK2^{V617F}$; Exon 12 BCR/ABL Fusion Transcript. <i>Acta Haematologica</i> , 2019, 141, 23-27.	1.4	6
263	Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 117-128.	1.4	6
264	The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden. <i>Blood</i> , 2019, 134, 1674-1674.	1.4	6
265	The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 $\times 10^9/L$ to $< 100 \times 10^9/L$) at Baseline. <i>Blood</i> , 2020, 136, 4-5.	1.4	6
266	Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval. <i>Blood</i> , 2020, 136, 46-47.	1.4	6
267	Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia. <i>Blood</i> , 2020, 136, 43-44.	1.4	6
268	STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. <i>Journal of Immunology</i> , 2022, 208, 2847-2855.	0.8	6
269	Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. <i>Leukemia Research</i> , 2013, 37, 1472-1476.	0.8	5
270	TP53 mutation is rare in primary myelofibrosis. <i>Leukemia and Lymphoma</i> , 2013, 54, 1552-1552.	1.3	5

#	ARTICLE	IF	CITATIONS
271	Paroxysmal nocturnal hemoglobinuria is not a cause of anemia in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2014, 55, 2215-2216.	1.3	5
272	Changing myelofibrosis's natural course at last. <i>Blood</i> , 2014, 123, 1776-1777.	1.4	5
273	Myeloproliferative neoplasm questionnaire: assessing patient disease knowledge in the modern digital information era. <i>Leukemia and Lymphoma</i> , 2021, 62, 2253-2260.	1.3	5
274	Two Phase 1b Studies Evaluating the Safety and Tolerability of BET Inhibitors, ABBV-744 and Mivebresib, as Monotherapies and in Combination with Ruxolitinib or Navitoclax in Patients with Myelofibrosis. <i>Blood</i> , 2020, 136, 18-19.	1.4	5
275	Targeting cistrome and dysregulated transcriptome of post-MPN sAML. <i>Oncotarget</i> , 2017, 8, 93301-93302.	1.8	5
276	Experimental therapy in myelofibrosis with myeloid metaplasia. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 1555-1563.	4.1	4
277	Emerging drugs for myelofibrosis. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 555-570.	2.4	4
278	Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis. <i>Leukemia and Lymphoma</i> , 2014, 55, 5-6.	1.3	4
279	Clinical value of event-free survival in acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 1690-1699.	5.2	4
280	Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 224-229.	0.4	4
281	Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis. <i>Blood</i> , 2019, 134, 4178-4178.	1.4	4
282	Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes. <i>Acta Haematologica</i> , 2022, 145, 448-453.	1.4	4
283	Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. <i>Blood Cancer Journal</i> , 2022, 12, 23.	6.2	4
284	Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT) study. <i>British Journal of Haematology</i> , 2022, 198, 1065-1068.	2.5	4
285	Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient. <i>Leukemia Research</i> , 2009, 33, e186-e188.	0.8	3
286	Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition. <i>Expert Review of Hematology</i> , 2012, 5, 631-641.	2.2	3
287	Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers. <i>Leukemia Research</i> , 2014, 38, 91-94.	0.8	3
288	Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 409-429.	2.2	3

#	ARTICLE	IF	CITATIONS
289	Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3. <i>Anticancer Research</i> , 2015, 35, 5219-23.	1.1	3
290	Trial in Progress: Phase Ib/II Study of Bcl-2/Bcl-XI Inhibitor Pelcitoclast (APG-1252) in Patients with Myelofibrosis (MF) That Progressed after Initial Therapy. <i>Blood</i> , 2020, 136, 15-16.	1.4	3
291	Ruxolitinib: the first agent approved for myelofibrosis. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 111-3.	0.3	3
292	Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. <i>Leukemia Research</i> , 2017, 57, 85-88.	0.8	2
293	Emerging drugs for essential thrombocythemia. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 93-105.	2.4	2
294	Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 191, e10-e13.	2.5	2
295	Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis. <i>Haematologica</i> , 2020, 106, haematol.2020.249441.	3.5	2
296	Association of transfusion independence with improved overall survival in myelofibrosis patients receiving momelotinib. <i>Journal of Clinical Oncology</i> , 2021, 39, 7046-7046.	1.6	2
297	The Impact of Anemia on Overall Survival in Patients with Myelofibrosis Treated with Ruxolitinib: An Exploratory Analysis of the Comfort Studies. <i>Blood</i> , 2015, 126, 1604-1604.	1.4	2
298	A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET) Tj ETQq0 O10rgBT /Overlock 10		
299	Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline "chemotherapy-free"™ therapy. <i>Leukemia and Lymphoma</i> , 2022, 63, 672-675.	1.3	2
300	Improved Survival of Patients with Myelofibrosis in the Last Decade. <i>Blood</i> , 2020, 136, 50-51.	1.4	2
301	Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis. <i>Scientific Reports</i> , 2022, 12, 4674.	3.3	2
302	Managing patients with myelofibrosis and thrombocytopenia. <i>Expert Review of Hematology</i> , 2022, , 1-9.	2.2	2
303	Impact of SF3B1 mutation in myelofibrosis. <i>Leukemia and Lymphoma</i> , 2022, 63, 2701-2705.	1.3	2
304	Is there still a role for interferon-alpha for newly diagnosed chronic myeloid leukemia in chronic phase?. <i>Leukemia and Lymphoma</i> , 2007, 48, 445-446.	1.3	1
305	Granulocytic sarcoma with massive scalp involvement. <i>American Journal of Hematology</i> , 2008, 83, 340-342.	4.1	1
306	Treatment of myelofibrosis in younger patients: To transplant or not?. <i>American Journal of Hematology</i> , 2009, 84, 131-132.	4.1	1

#	ARTICLE	IF	CITATIONS
307	SOHO State of the Art Updates and Next Questions: Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 191-199.	0.4	1
308	New Therapies in Development for Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S69-S71.	0.4	1
309	MPN-148: Momelotinib Dose-Intensity is Maintained in JAK Inhibitor-Na ⁺ ve and Previously JAK Inhibitor-Treated Intermediate-/High-Risk Myelofibrosis Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S330.	0.4	1
310	Poster: MPN-106: Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Na ⁺ ve Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Status. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S231.	0.4	1
311	Real-World Patient Characteristics and Treatment Patterns of Ruxolitinib Among Patients With Advanced Essential Thrombocythemia at Community Clinical Practice. <i>Leukemia Research</i> , 2021, 110, 106711.	0.8	1
312	Changes in the Incidence and Overall Survival of Patients with Myeloproliferative Neoplasms between 2002 and 2016 in the United States. <i>Blood</i> , 2020, 136, 12-13.	1.4	1
313	Pharmacotherapy of polycythemia vera. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 977-985.	0.8	0
314	Preface. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 81-82.	1.7	0
315	Therapy of Myelofibrosis: Where We Are and What Next. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S93-S95.	0.4	0
316	JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis. <i>Leukemia Research</i> , 2017, 63, 53-55.	0.8	0
317	Potential New Therapeutic Approaches for Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S130-S133.	0.4	0
318	Characteristics and Outcomes Of Patients (pts) With Multiple Myeloma (MM) Who Develop Therapy (t)-Related Myelodysplastic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), Or t-Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013, 122, 1424-1424.	1.4	0
319	Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. <i>Hematological Oncology</i> , 2022, 40, 491-504.	1.7	0
320	Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. <i>Modern Pathology</i> , 0, , .	5.5	0